BlueRidge Life Sciences Pharmaceutical Commercialization’s Dr. Naomi Sacks’s work published in Obesity Science & Practice on behalf of The Obesity Society was recently ranked within the top 10% of most-viewed papers published by the journal in 2023. In their study, Dr. Sacks and colleagues used national survey data to examine clinical, economic, and health-related quality-of-life outcomes associated with being overweight and obesity. They found evidence that being overweight and obesity are significantly associated with obesity-related comorbidities, poorer health-related quality of life, decreased mobility and productivity, and greater levels of disability. The also reported very low rates of anti-obesity medication use during the study period.
The article is open access, and can be read in full on the journal website: Clinical, economic, and health‐related quality of life outcomes in patients with overweight or obesity in the United States: 2016–2018.